{"id":644131,"date":"2023-03-23T19:32:02","date_gmt":"2023-03-23T19:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=644131"},"modified":"2023-03-23T19:32:02","modified_gmt":"2023-03-23T19:32:02","slug":"malignant-glioma-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/malignant-glioma-market-analysis-of-epidemiology-pipeline-therapies-and-key-companies-working-in-the-market_644131.html","title":{"rendered":"Malignant Glioma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market"},"content":{"rendered":"
\n
\"Malignant<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Malignant Glioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Malignant Glioma, historical and forecasted epidemiology as well as the Malignant Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Malignant Glioma Market Insights, Epidemiology, and Market Forecast-2032<\/a>“<\/strong> report delivers an in-depth understanding of the Malignant Glioma, historical and forecasted epidemiology as well as the Malignant Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

Got queries? Click here to know more about Malignant Glioma Market Landscape<\/a><\/strong><\/p>\n

\"\"<\/strong><\/p>\n

Malignant Glioma Overview<\/strong><\/p>\n

Glioma is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function. Three types of glial cells can produce tumors. Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor’s genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work<\/p>\n

Malignant Glioma Epidemiology Insights<\/strong><\/p>\n

Glioblastoma is the most aggressive malignant primary brain tumor. With an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years, it is uncommon in children. The incidence is 1.6 times higher in males compared to females and 2.0 times higher in Caucasians compared to Africans and Afro-Americans, with a lower incidence in Asians and American Indians. Commonly located in the supratentorial region (frontal, temporal, parietal, and occipital lobes) and is rarely located in the cerebellum. Genetic and environmental factors have been investigated in GBM. Risk factors include prior radiotherapy, decreased susceptibility to allergy, immune factors, and immune genes, as well as some single nucleotide polymorphisms detected by genomic analysis. The use of anti-inflammatory medication has been found to be protective.Survival from GBM is poor; only a few patients survive 2.5 years and less than 5% of patients survive 5 years following diagnosis. Survival rates for patients with Molecular epidemiology integrates molecular technology into epidemiological studies and outcomes. The future of the epidemiology will depend on multicenter studies generating large clinical data sets of genomic data potentially leading to further understanding of the roles of genes and environment in the development of this devastating disease<\/p>\n

Malignant Glioma Epidemiology Segmentation<\/strong><\/p>\n